{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:03:39Z","timestamp":1782846219815,"version":"3.54.5"},"reference-count":29,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Chronic hand eczema (CHE) is a prevalent inflammatory skin disease in clinical practice. Guidelines recommend the use of topical medications, including corticosteroids and calcineurin inhibitors; however, prolonged use of these drugs may result in adverse effects, such as skin atrophy, drug tolerance, and rebound phenomena. Moreover, these medications exhibit limited efficacy in managing chronic hypertrophic hand eczema. Traditional Chinese medicine (TCM) has a long history of treating patients. The Runzaozhiyang lotion (RZZYL) is often used in the Department of Dermatology of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, for these patients, with marked efficacy on symptoms, keratinization, hypertrophy, and pruritus improvements. Nonetheless, there is still no high-quality evidence from evidence-based medicine to prove the effectiveness and safety of CHE treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to examine the efficacy and safety of a classic Chinese herbal prescription, RZZYL, for CHE and to provide a different treatment option for patients with hand eczema who are resistant to conventional Western pharmaceutical treatments.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This study is a clinical trial characterized as randomized, double-blind, double-dummy, and positive drug-controlled. A total of 122 patients diagnosed with CHE have been randomized and allocated in a 1:1 ratio into 2 distinct groups, with one receiving the intervention and the other serving as the control. Participants in the intervention group will receive RZZYL granules along with a placebo cream of mometasone furoate, whereas the control group will get mometasone furoate cream in combination with a placebo for RZZYL granule. Both groups will be treated with either the active drug or a placebo for 4 weeks. The primary outcome metrics are the Hand Eczema Severity Index (HECSI) and the Numerical Rating Scales (NRS). Secondary outcome metrics consist of the target lesion area score, the Patient-Oriented Eczema Measure (POEM), the Dermatology Life Quality Index (DLQI), and the Investigator Global Assessment (IGA). The outcomes will be assessed at the start of the study and again at 2 and 4 weeks after the treatment period.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study will be conducted according to the guidelines and regulations approved by the participating institutions. Recruitment is expected to commence in March 2025 and conclude in March 2026. Data collection is anticipated to be completed by June 2026, with the study expected to conclude in August 2026.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This protocol addresses the limitations of previous research and aims to explore the efficacy and safety of RZZYL in treating CHE through a higher-quality clinical study. It seeks to provide additional treatment options for patients with CHE who are resistant to or have poor responses to current therapies.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/76555","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:45:07Z","timestamp":1756457107000},"page":"e76555-e76555","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Runzaozhiyang Lotion for Chronic Hand Eczema: Protocol for a Randomized Controlled Trial"],"prefix":"10.2196","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4773-442X","authenticated-orcid":false,"given":"Rui","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1894-2368","authenticated-orcid":false,"given":"Chen-Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-1383","authenticated-orcid":false,"given":"Bing-Nan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7842-3977","authenticated-orcid":false,"given":"Jia-Ning","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4944-9354","authenticated-orcid":false,"given":"Ao-Lin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1508-6463","authenticated-orcid":false,"given":"Fan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-277X","authenticated-orcid":false,"given":"Jiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"6","key":"R1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40257-024-00890-z","article-title":"Chronic hand eczema","volume":"25","author":"Weisshaar","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"R2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/cod.14133","article-title":"Hand hygiene and hand eczema: a systematic review and meta\u2010analysis","volume":"87","author":"Loh","journal-title":"Contact Derm"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S292504","article-title":"Drugs for the treatment of chronic hand eczema: successes and key challenges","volume":"16","author":"Dubin","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"R4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","article-title":"Guidelines for diagnosis, prevention, and treatment of hand eczema","volume":"86","author":"Thyssen","journal-title":"Contact Derm"},{"issue":"8","key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015064.pub2","article-title":"Topical anti-inflammatory treatments for eczema: network meta-analysis","volume":"8","author":"Lax","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bjd.21037","article-title":"The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial","volume":"187","author":"Worm","journal-title":"Br J Dermatol"},{"issue":"3","key":"R7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12840","article-title":"Current and emerging therapies for hand eczema","volume":"32","author":"Lee","journal-title":"Dermatol Ther"},{"issue":"11","key":"R8","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00959-9","article-title":"Traditional Chinese medicine (TCM) and allergic diseases","volume":"20","author":"Chan","journal-title":"Curr Allergy Asthma Rep"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4961691","article-title":"Antipruritic effect of Qingpeng ointment on the localized nonexudative eczema","volume":"2019","author":"Li","journal-title":"Evid Based Complement Alternat Med"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5594953","article-title":"Efficacy and safety of Qingpeng ointment for subacute and chronic eczema: a systematic review and meta-analysis","volume":"2021","author":"Li","journal-title":"Biomed Res Int"},{"issue":"2","key":"R11","first-page":"160","volume":"37","author":"Chang","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114247","article-title":", a traditional Chinese medicine: comprehensive review of botany, traditional uses, chemical composition, pharmacology and toxicology","volume":"278","author":"Ren","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"R13","doi-asserted-by":"publisher","DOI":"10.3390\/biom10050752","article-title":"A comprehensive review of the phytochemical, pharmacological, and toxicological properties of L","volume":"10","author":"\u0218tef\u0103nescu","journal-title":"Biomolecules"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2024.106214","article-title":"Phytochemistry and pharmacological activities of Cannabis sativa fruit (Cannabis Fructus)","volume":"179","author":"Guo","journal-title":"Fitoterapia"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.114033","article-title":"Application of polysaccharide hydrogel for wound healing among in diabetes","volume":"241","author":"Li","journal-title":"Colloids Surf B Biointerfaces"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01168","article-title":"Chemical constituents, pharmacologic properties, and clinical applications of","volume":"10","author":"Xu","journal-title":"Front Pharmacol"},{"issue":"28","key":"R17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043234","article-title":"Network pharmacology study to reveal active compounds of Fructus Cnidii against oral cancer by regulating the inflammatory microenvironment","volume":"104","author":"Li","journal-title":"Medicine (Abingdon)"},{"issue":"2","key":"R18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1248\/bpb.25.260","article-title":"Antipruritic effect of Cnidii Monnieri Fructus (Fruits of CUSSON)","volume":"25","author":"Matsuda","journal-title":"Biol Pharm Bull"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118210","article-title":"Radix Sophorae Flavescentis of Sophora flavescens Aiton inhibits LPS-induced macrophage pro-inflammatory response via regulating CFHR2 expression","volume":"331","author":"Wu","journal-title":"J Ethnopharmacol"},{"issue":"24","key":"R20","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.26355\/eurrev_202312_34766","article-title":"Analysis of the mechanism of Sophorae Flavescentis Radix in the treatment of intractable itching based on network pharmacology and molecular docking","volume":"27","author":"Xiao","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"R21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004055.pub2","article-title":"Interventions for hand eczema","volume":"4","author":"Christoffers","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"R22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.13935\/j.cnki.sjzx.220221","article-title":"Clinical observation on the treatment of keratotic hand eczema with external application of Chinese medicine Runzao Zhiyang prescription","volume":"17","author":"Fan","journal-title":"Journal of Integrated Traditional and Western Medicine"},{"key":"R23","unstructured":"Bian Z . Chinese Clinical Dermatology (2 Volumes). 2nd ed. Jiangsu Phoenix Science and Technology Publishing House; 2017. URL: https:\/\/service.ppm.cn\/search.[Accessed 04-08-2025] ISBN: 978-7-5537-7142-7"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1859-x","article-title":"Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review","volume":"18","author":"Althunian","journal-title":"Trials"},{"issue":"1S","key":"R25","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.chest.2020.03.010","article-title":"Sample size estimation in clinical research: from randomized controlled trials to observational studies","volume":"158","author":"Wang","journal-title":"Chest"},{"issue":"1","key":"R26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.35541\/cjd.20200281","article-title":"Chinese Expert Consensus on the Diagnosis and Treatment of Hand Eczema (2021 Edition)","volume":"54","author":"Scientific Committee of the Dermatology Branch of the Chinese Medical Association","journal-title":"Chin J Dermatol"},{"key":"R27","author":"Dermatology Branch of the Chinese Society of Traditional Chinese Medicine","journal-title":"Chin J Dermatovenerol Integr Tradit West Med"},{"issue":"3","key":"R28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4097\/kja.19049","article-title":"Randomization in clinical studies","volume":"72","author":"Lim","journal-title":"Korean J Anesthesiol"},{"issue":"2","key":"R29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","article-title":"The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability","volume":"152","author":"Held","journal-title":"Br J Dermatol"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e76555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:08:10Z","timestamp":1782842890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e76555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2196\/76555","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"article-number":"v14i6e76555"}}